This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endologix Reports 33% Revenue Growth For The Second Quarter 2013

IRVINE, Calif., July 30, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2013.

John McDermott, Endologix President and Chief Executive Officer, said, "Our second quarter revenue was in-line with preliminary results released earlier this month. We continue to generate positive momentum globally with our AFX® Endovascular AAA System, which was supported by the launch of our U.S. PEVAR training program during the quarter. There has been strong interest in PEVAR from current and new physician customers, who will continue to be trained throughout the year. In Europe, our controlled market release of the Nellix® EndoVascular Aneurysm Sealing System is tracking to plan, providing us an excellent opportunity to further enhance the procedure and training ahead of a broader commercial launch anticipated in 2014."

Financial Results

Global revenue in the second quarter of 2013 was $34.0 million, a 33% increase from $25.5 million in the second quarter of 2012. For the six months ended June 30, 2013, global revenue increased 27% to $63.7 million, compared to $50.0 million for the six months ended June 30, 2012.

U.S. revenue in the second quarter of 2013 was $26.4 million, a 23% increase compared with $21.4 million in the second quarter of 2012. The increase was driven by continued adoption of the AFX system and by productivity gains from prior period expansion of the U.S. sales force including the addition of clinical specialists who provide field support to sales representatives. International revenue was $7.6 million, an 81% increase compared to $4.2 million in the second quarter of 2012. The international sales increase is primarily attributable to strong procedural growth and to the transition to a direct sales organization in Europe, which began in September 2011.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.95 -2.00%
FB $116.70 -0.03%
GOOG $692.75 0.25%
YHOO $36.45 -0.38%
TSLA $244.07 -1.50%


Chart of I:DJI
DOW 17,717.86 -112.90 -0.63%
S&P 500 2,068.87 -6.94 -0.33%
NASDAQ 4,788.6690 -16.6220 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs